Literature DB >> 9052869

Function of killer cell inhibitory receptors for MHC class I molecules.

F Vély1, L Olcese, M Bléry, E Vivier.   

Abstract

NK- and T-cells express at their surface, members of a multigenic family of killer-cell inhibitory receptors (KIR) for MHC Class I molecules. KIR engagement leads to the inhibition of NK- and T-cell activation programs. These receptors recruit the protein tyrosine phosphatases (PTPase), SHP-1 and SHP-2, upon tyrosine phosphorylation of immunoreceptor tyrosine-based inhibition motif (ITIM) expressed in both human and mouse KIR. We further define the ITIM amino acids sequence required in that recognition and demonstrate the critical role of the phosphoY-2 amino acid residue in this V/IxYxxL/V motif. In addition, using RBL-2H3 cells expressing endogenous Fc epsilonRI receptors as well as transfected CD25/CD3zeta chimera and p58.183 human KIR, we show that KIR inhibitory function requires co-engagement of KIR and ITAM-containing receptors. These results document the pathway used by KIR to down-regulate NK- and T-cell activation programs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9052869     DOI: 10.1016/s0165-2478(96)02664-8

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  3 in total

1.  Formation of a WIP-, WASp-, actin-, and myosin IIA-containing multiprotein complex in activated NK cells and its alteration by KIR inhibitory signaling.

Authors:  Konrad Krzewski; Xi Chen; Jordan S Orange; Jack L Strominger
Journal:  J Cell Biol       Date:  2006-04-10       Impact factor: 10.539

2.  Identification of the mouse killer immunoglobulin-like receptor-like (Kirl) gene family mapping to chromosome X.

Authors:  Alice Y Welch; Masanori Kasahara; Lisa M Spain
Journal:  Immunogenetics       Date:  2003-02-04       Impact factor: 2.846

Review 3.  Two to Tango: Co-evolution of Hominid Natural Killer Cell Receptors and MHC.

Authors:  Emily E Wroblewski; Peter Parham; Lisbeth A Guethlein
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.